Profound Medical Receives U.S. FDA 510(k) Clearance for TULSA …
TORONTO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical
Profound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases. “We are honored that the TULSA application was approved by the AMA’s CPT ® Editorial Panel for Category I code status,” said Profound’s CEO and Chairman, Arun Menawat.
Profound Medical Announces Preliminary Unaudited Fourth …
TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Announces First Patients Treated in Prospective ...
TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Flagship-run ProFound unveils with $75M to develop protein trove
May 26, 2022 · Fifteen years after scientists whittled down the estimated number of protein-coding genes to roughly 20,500, ProFound Therapeutics, a new company launched by Flagship Pioneering, says there are...
ProFound Therapeutics
Illuminating the Unknown. REVEALING A UNIVERSE OF NEW MEDICINES. ProFound™ Therapeutics is pioneering the expanded human proteome. Our Science. Where we Began. What if the human proteome were larger than we imagined?
ProFound Therapeutics
CAMBRIDGE, Mass., May 26, 2022 – Flagship Pioneering, the bioplatform innovation company, today unveiled ProFound™ Therapeutics, a company that has identified a universe of previously undiscovered human proteins, enabling a multitude of new therapeutic targets and medicines.
News - profoundtx.com
Flagship-Backed ProFound Therapeutics Scores $75M to Explore Undiscovered Proteins. Proteome-Focused ProFound Emerges From Flagship Pioneering. Flagship’s latest startup launches with bold claim: the discovery of thousands of new human proteins.
Profound Medical Corp. (PROF) Latest Stock News - Seeking Alpha
Get the latest news and real-time alerts from Profound Medical Corp. (PROF) stock at Seeking Alpha.
iCAD's ProFound Detection Version 4.0 Gains FDA Clearance
2 days ago · Nov. 12, 2024, 08:00 AM. NASHUA, N.H., Nov. 12, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer ...